How should I assess disease activity in a patient with rheumatoid arthritis who is on disease-modifying antirheumatic drugs (DMARDs) and oral steroids and presents with multiple joint pain?

How to Check Rheumatoid Arthritis Disease Activity

Use validated composite disease activity measures that include joint counts—specifically the CDAI (Clinical Disease Activity Index) or SDAI (Simplified Disease Activity Index)—as these are the most practical and accurate tools for assessing disease activity in clinical practice. 1

Recommended Disease Activity Assessment Tools

The following composite measures are validated and recommended for routine clinical use:

Primary Recommended Measures

CDAI (Clinical Disease Activity Index) 1, 2

• Most practical for point-of-care use - requires no laboratory values or complex calculations
• Components: tender joint count (28 joints) + swollen joint count (28 joints) + patient global assessment (0-10 scale) + physician global assessment (0-10 scale)
• Simple numerical sum of these four components
• Disease activity thresholds:
  • Remission: ≤2.8
  • Low disease activity: ≤10
  • Moderate disease activity: 10-22
  • High disease activity: >22

SDAI (Simplified Disease Activity Index) 1, 3

• Similar to CDAI but adds CRP (mg/dL)
• Components: tender joint count (28 joints) + swollen joint count (28 joints) + patient global assessment (0-10) + physician global assessment (0-10) + CRP (mg/dL)
• Disease activity thresholds:
  • Remission: ≤3.3
  • Low disease activity: ≤11
  • Moderate disease activity: 11-26
  • High disease activity: >26

Alternative Measures

DAS28 (Disease Activity Score-28) 4, 5

• Uses 28-joint count with ESR or CRP
• Requires complex calculation
• Thresholds: DAS28-ESR >3.2 or DAS28-CRP indicates at least moderate disease activity
• Important caveat: DAS28 <2.6 is NOT sufficiently stringent for defining remission 6

Clinical Assessment Components

What to Examine and Document

Joint Assessment (28-joint count) 1

• Specific joints to assess bilaterally:
  • Proximal interphalangeal joints (1st-5th)
  • Metacarpophalangeal joints (1st-5th)
  • Wrists
  • Elbows
  • Shoulders
  • Knees
• Count tender joints (painful on pressure)
• Count swollen joints (palpable synovial thickening)

Patient-Reported Measures 1

• Patient global assessment of disease activity (0-10 visual analog scale)
• Pain assessment (0-10 scale)
• Health Assessment Questionnaire (HAQ) for functional status

Physician Assessment 1

• Physician/evaluator global assessment (0-10 visual analog scale)

Laboratory Markers 1

• CRP is preferred over ESR - more reliable, not age-dependent, simpler test
• Measuring both acute-phase reactants offers no additional clinical value
• CRP is the most clinically useful biomarker

Practical Implementation Algorithm

Step 1: Perform Joint Examination

Systematically assess all 28 joints for tenderness and swelling, documenting the count of each

Step 2: Obtain Patient and Physician Global Assessments

Use visual analog scales (0-10) - can be paper or electronic format

Step 3: Calculate Disease Activity Score

• For immediate point-of-care decision: Use CDAI (no lab needed)
• If CRP available: Use SDAI for slightly more comprehensive assessment

Step 4: Interpret Results and Act

Target: Remission (CDAI ≤2.8 or SDAI ≤3.3) 4, 6

• If target achieved: Continue current therapy
• If low disease activity (CDAI ≤10 or SDAI ≤11): Acceptable alternative goal, especially in established disease 1, 6
• If moderate/high disease activity: Treatment intensification required

Monitoring Frequency

Active disease: Every 1-3 months 6

• If no improvement by 3 months: Adjust therapy
• If target not reached by 6 months: Change treatment strategy 6

Stable disease at target: Every 6-12 months 6

Additional Considerations for Your Patient

Red Flags Suggesting Active Disease Beyond Joint Counts 5

Your patient on DMARDs and oral steroids with multiple joint pain may have:

• Inability to taper glucocorticoids below 7.5 mg/day prednisone equivalent 5
• Elevated acute-phase reactants (CRP/ESR) 5
• Imaging evidence of active synovitis (ultrasound can detect subclinical inflammation) 7

Ultrasound as Adjunct 7

While not required for routine monitoring, ultrasound can verify synovial inflammatory activity when clinical examination is equivocal, particularly assessing:

• Synovial hypertrophy
• Synovial vascularity (power Doppler)

Common Pitfalls to Avoid

1. Don't rely on DAS28 <2.6 alone for remission - use ACR-EULAR Boolean or index-based remission criteria (CDAI/SDAI) 4, 6

2. Don't use single measures in isolation - composite measures are more sensitive to change than individual assessments 1

3. Don't delay treatment adjustments - if no improvement by 3 months or target not reached by 6 months, therapy must be modified 6

4. Don't assume pain equals inflammation - some patients may have non-inflammatory pain (fibromyalgia, osteoarthritis) contributing to symptoms despite controlled RA 2

5. Beware of biologic agents affecting acute-phase reactants disproportionately - newer biologics targeting specific cytokines may deflate composite scores that include CRP/ESR 2